Status:

COMPLETED

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Lead Sponsor:

Incyte Corporation

Conditions:

MPN (Myeloproliferative Neoplasms)

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This was a randomized, double-blind study comparing the efficacy and safety of ruxolitinib (INCB018424) tablets to matching placebo tablets in patients diagnosed with Myelofibrosis (either Primary Mye...

Detailed Description

Patients with spleen growth of greater than 25% based on an increase in spleen volume from Baseline were eligible for early unblinding, and for patients on placebo, cross over to ruxolitinib prior to ...

Eligibility Criteria

Inclusion

  • Subjects must be diagnosed with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF) according to the 2008 World Health Organization criteria
  • Subjects with myelofibrosis requiring therapy must be classified as high risk OR intermediate risk level 2 according to the prognostic factors defined by the International Working Group
  • Subjects with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2 or 3
  • Subjects who have not previously received treatment with a Janus kinase (JAK) inhibitor

Exclusion

  • Subjects with a life expectancy of less than 6 months
  • Subjects with inadequate bone marrow reserve as demonstrated by specific clinical laboratory counts
  • Subjects with inadequate liver or renal function
  • Subjects with clinically significant bacterial, fungal, parasitic or viral infection which require therapy
  • Subjects with an active malignancy over the previous 5 years except specific skin cancers.
  • Subjects with severe cardiac conditions
  • Subjects who have had splenic irradiation within 12 months

Key Trial Info

Start Date :

August 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2015

Estimated Enrollment :

309 Patients enrolled

Trial Details

Trial ID

NCT00952289

Start Date

August 1 2009

End Date

October 1 2015

Last Update

March 12 2018

Active Locations (112)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 28 (112 locations)

1

Birmingham, Alabama, United States

2

Scottsdale, Arizona, United States

3

Baldwin Park, California, United States

4

Bellflower, California, United States